Jonah Shulman, MD

Caroline Cromwell, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. She is the Medical Director of the Thrombosis Services Program for the Mount Sinai Health System and Committee Leader for the Mount Sinai Hospital Anticoagulation Safety and VTE Prophylaxis Committee. Dr. Cromwell is also the Associate Medical Director for the Cardiovascular Surgery Bloodless Management Program for the Health System. Her clinical focus is on consultative non-malignant hematology. Dr. Cromwell treats patients with blood conditions, including deep vein thrombosis, thrombocytopenia, hematologic complications of pregnancy, anemia, and coagulation disorders at The Ruttenberg Treatment Center. Dr. Cromwell is active in teaching and mentorship. She received the Hematology/Oncology Fellowship Teaching Award in 2018 and serves as Senior Medical Student Faculty Advisor.

Dr. Ajai Chari, MD is a Oncology provider with Mount Sinai Health System. Learn more about Mount Sinai’s Oncology services here http://www.mountsinai.org/care/cancer.

Thomas Marron, MD, PhD, is Assistant Director of Immunotherapy and Early Phase Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. As a member of the Center for Thoracic Oncology, Dr. Marron treats thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. He leads numerous clinical trials for thoracic malignancies and hepatocellular carcinoma (liver cancer). He also leads the Phase 1 trials program at The Mount Sinai Hospital, where he enrolls patients into dozens of trials focused on development of novel cancer immunotherapies. As a member of The Tisch Cancer Institute and the Precision Immunology Institute, Dr. Marron works closely with basic scientists across the Mount Sinai Health System, translating preclinical findings into clinical advances. He leads a large translational neoadjuvant program focused on clinical trials for multiple types of cancer. The goal of these trials is to decrease the likelihood that cancer will return after surgery; in parallel, they support deep interrogation of the effect of new and standard therapies on the tumor immune microenvironment at the single-cell level. Further, the trials enable Dr. Marron and collaborators to define combination approaches that optimize response rates and the durability of novel immune-based therapies, while minimizing toxicity.